Ronen Shavit1, Ramit Maoz-Segal1, Irena Offengenden1, Soad Haj Yahia1, Diti Machnes Maayan2, Yulia Lifshitz2, Stanley Niznik1, Michal Deutch1, Eti Elbaz1, Hosney Genaim1, Mona Iancovici-Kidon2, Nancy Agmon-Levin3. 1. Clinical Immunology, Angioedema and Allergy Unit, Center for Autoimmune Diseases, Sheba Medical Center, Tel Hashomer, Israel. 2. Clinical Immunology, Angioedema and Allergy Unit, Center for Autoimmune Diseases, Sheba Medical Center, Tel Hashomer, Israel; Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel. 3. Clinical Immunology, Angioedema and Allergy Unit, Center for Autoimmune Diseases, Sheba Medical Center, Tel Hashomer, Israel; Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel. Electronic address: nancy.agmon-levin@sheba.health.gov.il.
Abstract
BACKGROUND: Allergic reactions to the coronavirus disease 2019 (COVID-19) vaccines have raised concerns, particularly as repeated doses are required. Skin tests with the vaccines excipient were found to be of low value, whereas the utility of skin tests with the whole vaccine is yet to be determined. OBJECTIVE: To evaluate a panel of skin tests and the outcomes of subsequent doses of immunization among subjects who suffered an immediate allergic reaction to the BioNTech (BNT162b2) COVID-19 vaccine. METHODS: Between March and December 2021, patients who experienced symptoms consistent with immediate allergic reactions to the BNT162b2 vaccine and were referred to the Sheba Medical Center underwent skin testing with polyethylene glyol (PEG)-containing medicines, Pfizer-BNT162b2, and Oxford-AstraZeneca vaccine (AZD1222). Further immunization was performed accordingly and under medical observation. RESULTS: A total of 51 patients underwent skin testing for suspected allergy to the COVID vaccines, of which 38 of 51 (74.5%) were nonreactive, 7 of 51(13.7%) had no skin sensitization but suffered a clinical reaction during skin testing (mainly cough), and 6 of 51 (11.7%) exhibited immediate skin sensitization. Both skin sensitization and cough during testing were related to a higher use of adrenaline following immunization (P = .08 and P = .024, respectively). Further immunization with the BNT162b2 vaccine was recommended unless sensitization or severe reaction to previous immunization was evident. The latter were referred to be tested/receive the alternative AZD1222 vaccine. Ten patients underwent skin testing with AZD1222: 2 of 10 (20%) demonstrated skin sensitization to both vaccines; thus, 8 of 10 were immunized with the AZD1222, of which 2 of 8 (25%) had allergic reactions. CONCLUSIONS: Immediate allergic reactions to COVID-19 vaccines are rare but can be severe and reoccur. Intradermal testing with the whole vaccine may discriminate sensitized subjects, detect cross-sensitization between vaccines, and enable estimation of patients at higher risk.
BACKGROUND: Allergic reactions to the coronavirus disease 2019 (COVID-19) vaccines have raised concerns, particularly as repeated doses are required. Skin tests with the vaccines excipient were found to be of low value, whereas the utility of skin tests with the whole vaccine is yet to be determined. OBJECTIVE: To evaluate a panel of skin tests and the outcomes of subsequent doses of immunization among subjects who suffered an immediate allergic reaction to the BioNTech (BNT162b2) COVID-19 vaccine. METHODS: Between March and December 2021, patients who experienced symptoms consistent with immediate allergic reactions to the BNT162b2 vaccine and were referred to the Sheba Medical Center underwent skin testing with polyethylene glyol (PEG)-containing medicines, Pfizer-BNT162b2, and Oxford-AstraZeneca vaccine (AZD1222). Further immunization was performed accordingly and under medical observation. RESULTS: A total of 51 patients underwent skin testing for suspected allergy to the COVID vaccines, of which 38 of 51 (74.5%) were nonreactive, 7 of 51(13.7%) had no skin sensitization but suffered a clinical reaction during skin testing (mainly cough), and 6 of 51 (11.7%) exhibited immediate skin sensitization. Both skin sensitization and cough during testing were related to a higher use of adrenaline following immunization (P = .08 and P = .024, respectively). Further immunization with the BNT162b2 vaccine was recommended unless sensitization or severe reaction to previous immunization was evident. The latter were referred to be tested/receive the alternative AZD1222 vaccine. Ten patients underwent skin testing with AZD1222: 2 of 10 (20%) demonstrated skin sensitization to both vaccines; thus, 8 of 10 were immunized with the AZD1222, of which 2 of 8 (25%) had allergic reactions. CONCLUSIONS: Immediate allergic reactions to COVID-19 vaccines are rare but can be severe and reoccur. Intradermal testing with the whole vaccine may discriminate sensitized subjects, detect cross-sensitization between vaccines, and enable estimation of patients at higher risk.
Authors: Ana Dioun Broyles; Aleena Banerji; Sara Barmettler; Catherine M Biggs; Kimberly Blumenthal; Patrick J Brennan; Rebecca G Breslow; Knut Brockow; Kathleen M Buchheit; Katherine N Cahill; Josefina Cernadas; Anca Mirela Chiriac; Elena Crestani; Pascal Demoly; Pascale Dewachter; Meredith Dilley; Jocelyn R Farmer; Dinah Foer; Ari J Fried; Sarah L Garon; Matthew P Giannetti; David L Hepner; David I Hong; Joyce T Hsu; Parul H Kothari; Timothy Kyin; Timothy Lax; Min Jung Lee; Kathleen Lee-Sarwar; Anne Liu; Stephanie Logsdon; Margee Louisias; Andrew MacGinnitie; Michelle Maciag; Samantha Minnicozzi; Allison E Norton; Iris M Otani; Miguel Park; Sarita Patil; Elizabeth J Phillips; Matthieu Picard; Craig D Platt; Rima Rachid; Tito Rodriguez; Antonino Romano; Cosby A Stone; Maria Jose Torres; Miriam Verdú; Alberta L Wang; Paige Wickner; Anna R Wolfson; Johnson T Wong; Christina Yee; Joseph Zhou; Mariana Castells Journal: J Allergy Clin Immunol Pract Date: 2020-10
Authors: Cosby A Stone; Yiwei Liu; Mary V Relling; Matthew S Krantz; Amanda L Pratt; Andrew Abreo; Jonathan A Hemler; Elizabeth J Phillips Journal: J Allergy Clin Immunol Pract Date: 2018-12-14
Authors: Nicola P Klein; Ned Lewis; Kristin Goddard; Bruce Fireman; Ousseny Zerbo; Kayla E Hanson; James G Donahue; Elyse O Kharbanda; Allison Naleway; Jennifer Clark Nelson; Stan Xu; W Katherine Yih; Jason M Glanz; Joshua T B Williams; Simon J Hambidge; Bruno J Lewin; Tom T Shimabukuro; Frank DeStefano; Eric S Weintraub Journal: JAMA Date: 2021-10-12 Impact factor: 56.272
Authors: Christopher Michael Warren; Theo Thomas Snow; Alexandra S Lee; Mihir Mukesh Shah; Anja Heider; Andra Blomkalns; Brooke Betts; Anthony S Buzzanco; Joseph Gonzalez; R Sharon Chinthrajah; Evan Do; Iris Chang; Diane Dunham; Grace Lee; Ruth O'Hara; Helen Park; Mohamed H Shamji; Lisa Schilling; Sayantani B Sindher; Deepak Sisodiya; Eric Smith; Mindy Tsai; Stephen J Galli; Cezmi Akdis; Kari C Nadeau Journal: JAMA Netw Open Date: 2021-09-01